OS Therapies reports statistically significant 3-year overall survival benefit for OST-HER2 in Phase 2b osteosarcoma trial

OS Therapies announced a statistically significant final 3-year overall survival benefit for OST-HER2-treated patients in its Phase 2b trial in pulmonary metastatic osteosarcoma, compared with a combined published historical control.

Detected & updated continuously · Source: Nebula